Single-molecule analysis sheds light on cardiac myosin dysfunction due to hypertrophic cardiomyopathy mutation A57D in ventricular myosin light chain-1 (MLC1v)

This study utilizes single-molecule analysis and computational modeling to demonstrate that the A57D mutation in the ventricular myosin light chain-1 (MLC1v) causes hypertrophic cardiomyopathy by altering lever arm flexibility, which reduces powerstroke size, slows actomyosin detachment, and increases calcium sensitivity, ultimately leading to impaired cardiac muscle relaxation.

The Gist

The Big Picture: A Broken Engine in the Heart

Imagine your heart is a high-performance car engine. Inside this engine, there are millions of tiny pistons called myosin motors. These pistons pull on ropes (actin filaments) to squeeze the heart muscle, pumping blood throughout your body.

For this engine to run smoothly, the pistons need to grab the rope, pull hard, let go quickly, and reset for the next pull. This cycle happens thousands of times per minute.

This study investigates a specific type of heart disease called Hypertrophic Cardiomyopathy (HCM). In this condition, the heart muscle gets dangerously thick and stiff, making it hard to pump blood. The researchers found that in one specific patient, the "engine" was broken not because of the main piston, but because of a tiny, crucial screw holding the piston together.

The Culprit: A Tiny Screw with a Big Problem

The "screw" in question is a protein called MLC1v. Think of it as a specialized wrench or a stabilizer bar attached to the myosin motor.

• The Mutation: In this patient, one single letter in their DNA code was wrong. This changed a tiny building block (Alanine) in the MLC1v screw into a different one (Aspartate).
• The Result: This tiny change didn't just break the screw; it changed the entire shape and flexibility of the motor's "arm" (the lever arm).

What Went Wrong? (The Three Main Glitches)

The researchers used a super-powerful microscope (an optical trap) to watch these motors work one by one. They found three major problems with the mutant motors compared to healthy ones:

1. The "Sticky" Problem (Slower Detachment)

• Normal Motor: Imagine a person rowing a boat. They pull the oar through the water, then quickly lift it out to reset for the next stroke.
• Mutant Motor: The mutant motor is like a rower who gets their oar stuck in the mud. Once it grabs the rope, it refuses to let go quickly.
• The Consequence: Because the motor stays stuck longer, the heart muscle can't relax fast enough between beats. This leads to a heart that is stiff and can't fill with blood properly (diastolic dysfunction).

2. The "Short Step" Problem (Reduced Powerstroke)

• Normal Motor: A healthy motor takes a long, powerful step, pulling the rope about 5 nanometers (a tiny distance, but huge for a molecule).
• Mutant Motor: The mutant motor is like a person with a limp. It tries to pull, but its step is much shorter (only about 3.4 nanometers).
• The Consequence: Even if the motor pulls, it doesn't move the rope very far. The heart muscle becomes weaker and slower.

3. The "Rigid Arm" Problem (Increased Stiffness)

• Normal Motor: The arm of the motor is flexible, like a spring. It can bend and absorb shock, allowing for smooth movement.
• Mutant Motor: The mutation made the arm stiff, like a steel rod. It lost its flexibility.
• The Consequence: A stiff arm can't swing as freely. It creates a jerky, inefficient motion. The researchers found that this stiffness was the same whether the motor was pulling or resting, meaning it was "locked" in a rigid state.

How Did They Figure This Out?

Since they couldn't study the patient's heart directly without surgery, they used a clever trick: Reconstitution.

1. The Source: They took a tiny sample of heart tissue from the patient (who had a rare "homozygous" mutation, meaning all their motors were broken, not just half).
2. The Swap: They took healthy human heart motors and swapped out the broken "screws" (MLC1v) with the mutant ones in a lab dish.
3. The Test: They watched these "Frankenstein" motors. The result? The motors with the mutant screws behaved exactly like the ones from the patient's heart. This proved that the mutation alone was the cause of the problem, not other factors in the patient's body.

The Computer Simulation: Seeing the Invisible

To understand why the motor was broken, they used a supercomputer to run a Molecular Dynamics Simulation.

• The Analogy: Imagine taking a high-speed video of a dancer's arm. In the healthy version, the arm curves gracefully. In the mutant version, the computer showed that the "screw" change forced the arm to straighten out and lose its curve.
• The Chain Reaction: Because the arm straightened, it pulled on other parts of the motor, changing how the motor held its fuel (ATP/ADP). This created a ripple effect, making the whole machine slower and stiffer.

The Bigger Picture: Why This Matters

This study is a detective story that solved a mystery at the molecular level.

1. It explains the symptoms: The "sticky" motors explain why the heart can't relax (leading to shortness of breath). The "short steps" explain why the heart can't pump hard enough.
2. It offers a new tool: Because they successfully swapped the screws in the lab, doctors and scientists can now create "test engines" for other heart diseases without needing to cut open patients. They can test new drugs on these reconstituted motors to see if they fix the "sticky" or "short step" problems.
3. It highlights the importance of small parts: It shows that a tiny change in a small protein (the screw) can cause a massive failure in the whole engine (the heart).

Summary

The heart of this study is that a tiny typo in the DNA changed a tiny screw in the heart's engine. This made the engine sticky, short-stepped, and rigid, causing the heart to thicken and fail. By understanding exactly how this tiny screw broke the engine, scientists can now design better tools and medicines to fix it.

Technical Summary

1. Problem Statement

Hypertrophic Cardiomyopathy (HCM) is a leading cause of sudden cardiac death, often caused by mutations in sarcomeric proteins. While mutations in the myosin heavy chain are well-studied, mutations in the ventricular myosin light chain-1 (MLC1v) are rarer (<5% of cases) but associated with severe, early-onset HCM.

• The Specific Challenge: Most HCM patients are heterozygous (carrying both wild-type and mutant alleles), making it difficult to isolate the direct functional effects of the mutation in ensemble measurements due to the mixture of normal and mutant motors.
• The Gap: The molecular mechanism by which the A57D mutation (Alanine to Aspartate at position 57) in MLC1v alters the biomechanics of the $\beta$-cardiac myosin (MII) motor and leads to pathological remodeling is not fully understood.
• The Opportunity: The authors had access to a rare homozygous patient sample (where 100% of the MLC1v is mutant), allowing for the study of a pure population of mutant motors without wild-type interference.

2. Methodology

The study employed a multi-scale approach combining patient tissue analysis, single-molecule biophysics, protein reconstitution, and computational modeling.

• Sample Source:
  • Mutant (MUT): Septal myectomy tissue from a 52-year-old male with homozygous MYL3 c.170C>A (A57D) mutation.
  • Wild-Type (WT): Donor heart tissue from a 56-year-old male (non-diseased).
• Tissue-Level Analysis: Immunohistochemistry was performed to assess cardiomyocyte disarray, fibrosis, gap junction distribution (Connexin-43, N-Cadherin), and myosin heavy chain isoform composition ($\alpha$- vs. $\beta$-MyHC).
• Single-Molecule Optical Trapping (3-bead assay):
  • Native full-length $\beta$-cardiac myosin was extracted and analyzed.
  • Parameters Measured: Actomyosin (AM) attachment lifetime ($t_{on}$), detachment rate ($k_{off}$), powerstroke size ($\delta$), and cross-bridge stiffness ($k$) under varying ATP concentrations.
  • Techniques: Variance-covariance and ramp methods were used to derive stiffness; ensemble averaging was used to resolve sub-steps of the powerstroke.
• Protein Reconstitution:
  • Due to limited tissue, a novel reconstitution system was developed where native human $\beta$-myosin (from donor tissue) had its endogenous MLC1v exchanged with recombinant WT or MUT (A57D) MLC1v.
  • In Vitro Motility Assay: Actin filament gliding speeds were measured for native, reconstituted WT, and reconstituted MUT myosins to validate the single-molecule findings at the ensemble level.
• Computational Modeling:
  • Molecular Dynamics (MD) Simulations: Simulated the post-powerstroke state (AM.ADP*) to analyze structural changes in the lever arm, tail curvature, and residue interactions.
  • FiberSim Modeling: Used experimentally derived kinetic and mechanical parameters to simulate sarcomere-level twitch kinetics and force-pCa relationships.

3. Key Results

A. Tissue-Level Pathology

• The patient tissue exhibited classic HCM features: cardiomyocyte disarray, interstitial fibrosis, and mislocalization of gap junction proteins (Connexin-43, N-Cadherin).
• Isoform Heterogeneity: Unlike the donor tissue, the patient tissue showed increased expression of the atrial isoform ($\alpha$-MyHC) alongside $\beta$-MyHC, creating a heterogeneous population of motors within the sarcomeres.

B. Single-Molecule Biomechanics (Optical Trap)

The A57D mutation caused profound changes in the chemomechanical cycle of the myosin motor:

1. Slower Detachment Kinetics:
   • The mutant myosin showed a ~3-fold reduction in the actomyosin detachment rate ($k_{cat}$: 26.5 $s^{-1}$ for MUT vs. 74.5 $s^{-1}$ for WT).
   • The mutation increased ATP sensitivity (lower $K_{0.5}$), suggesting the rate-limiting step is ADP release, which is significantly slowed.
2. Reduced Powerstroke Size:
   • Total stroke size decreased from 5.07 nm (WT) to 3.4 nm (MUT).
   • Both the first powerstroke (linked to Pi release) and the second powerstroke (linked to ADP release) were reduced in amplitude.
3. Increased Cross-Bridge Stiffness:
   • In WT myosin, stiffness is lower in the ADP-bound state (0.62 pN/nm) compared to the rigor state (1.93 pN/nm).
   • In MUT myosin, this difference vanished; the ADP-bound state exhibited high stiffness (~1.7–2.0 pN/nm), similar to the rigor state. The mutant lever arm appears "stiffer" throughout the cycle.
4. Reduced Gliding Speed:
   • Reconstituted MUT myosin drove actin filaments significantly slower (398 nm/s) compared to WT (535 nm/s), consistent with the single-molecule data ($V = \text{stroke} / t_{on}$).

C. Molecular Dynamics Simulations

• The A57D substitution (Alanine $\to$ Aspartate) introduced a negative charge in the hydrophobic core of the MLC1v N-terminal helix.
• Structural Consequences:
  • The mutation altered interactions between MLC1v, the Myosin Heavy Chain (MyHC) tail (specifically residue Y801), and MLC2v.
  • This led to a ~33% reduction in the curvature of the MyHC tail (pliant region) and reduced flexibility (lower RMSF).
  • The lever arm became more linear and rigid, preventing the full swing required for a large powerstroke.
  • Allosteric changes were observed in the nucleotide-binding pocket, affecting ADP conformation.

D. Sarcomere-Level Modeling (FiberSim)

• Simulations predicted that the MUT myosin would cause:
  • Slower relaxation: Prolonged time to 50% relaxation (263 ms vs. 180 ms).
  • Increased Calcium Sensitivity: Higher force generation at lower calcium concentrations (pCa50 shift).
  • Reduced Peak Velocity: Slower time-to-peak force.

4. Key Contributions

1. Direct Characterization of Pure Mutant Motors: By utilizing a rare homozygous patient sample, the study isolated the primary functional defects of the A57D mutation without the confounding effects of wild-type myosin co-expression.
2. Mechanistic Link Between Structure and Function: The study established a direct causal chain: A57D mutation $\to$ altered MLC1v-MyHC interactions $\to$ reduced lever arm flexibility/curvature $\to$ increased stiffness and reduced powerstroke $\to$ slowed ADP release.
3. Validation of Reconstitution Strategy: The authors successfully demonstrated that recombinant MLC1v can be exchanged into native human cardiac myosin to create functional models. This provides a critical alternative for studying HCM mutations when patient tissue is unavailable.
4. Discovery of Stiffness Phenotype: The finding that the mutant myosin loses the normal compliance difference between the ADP-bound and rigor states suggests a fundamental change in the energy landscape of the cross-bridge cycle.

5. Significance

• Pathophysiological Insight: The study explains the diastolic dysfunction characteristic of HCM. The slowed detachment rate and increased stiffness prevent the heart muscle from relaxing quickly, leading to impaired filling and reduced end-diastolic volume.
• Therapeutic Implications: Understanding that the mutation increases stiffness and slows kinetics suggests that therapeutic strategies should aim to accelerate ADP release or reduce cross-bridge stiffness (e.g., using myosin inhibitors like mavacamten, though specific efficacy for this mutation requires further testing).
• Methodological Advance: The successful reconstitution of human full-length myosin with specific light chain mutations sets a new standard for future mechanistic studies of sarcomeric diseases, bridging the gap between animal models and human physiology.

In summary, this paper elucidates how a single point mutation in a regulatory light chain propagates structural changes to the lever arm, fundamentally altering the motor's mechanics to cause the pathological features of hypertrophic cardiomyopathy.